Role of Enzymes in Pharmaceutical and Biotechnology Industries

  • Bhupender Singu
  • Uday Annapure


In the modern world, enzymes are not just catalysts but also “tools” that modify the process based on the requirement. Enzymes hold key functions in the reactions where other alternatives fail to deliver the desired outputs. The main features of enzymes are their specificity, reusability, and non-formation of unwanted by-products that may contaminate the product as well as the environment. These features have made enzymes a popular choice in the biopharmaceutical sector. The increased use of enzymes is also attributed to high efficiency and low cost achieved by adapting modern techniques such as strain improvement, mutations, genetic engineering, recombinant DNA technology, etc. Additionally, the enzyme activity can be controlled by physical or chemical methods making them applicable to a wide range of processes. Enzyme application in various fields is possible due to the continuous research in biotechnology. The global market of enzymes in the industrial sector is valued at 4.91 billion USD in 2015 and is expected to reach 9.74 billion USD by 2022 as reported by Stratistics Market Research Consulting Pvt. Ltd. The pharmaceutical and biotechnology sectors contribute to a major share of revenue generation globally. This chapter provides an overview of enzymatic applications in the biopharmaceutical sector along with the current market scenario and expected future trends.


Enzymes Biotechnology Biocatalysts Biosensors Therapeutic enzymes 


  1. Ardelt W, Ardelt B, Darzynkiewicz Z (2009) Ribonucleases as potential modalities in anticancer therapy. Eur J Pharmacol 625(1–3):181–189. NIH Public AccessCrossRefPubMedPubMedCentralGoogle Scholar
  2. Blinc A et al (1991) Dependence of blood clot lysis on the mode of transport of urokinase into the clot – a magnetic resonance imaging study in vitro. Thromb Haemost 65(5):549–552CrossRefGoogle Scholar
  3. Booth C et al (2007) Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006). Clin Immunol 123(2):139–147. CrossRefPubMedGoogle Scholar
  4. Cipollone R et al (2008) Enzymatic detoxification of cyanide: clues from Pseudomonas aeruginosa Rhodanese. J Mol Microbiol Biotechnol 15(2–3):199–211. CrossRefPubMedGoogle Scholar
  5. Grumezescu AM (2017) Ingredients extraction by physicochemical methods in food. Elsevier Science, LondonCrossRefGoogle Scholar
  6. Kate Traynor (n.d.) FDA approves erwinaze for treatment of leukemiaGoogle Scholar
  7. Kayser O, Müller RH (2005) A primer on pharmaceutical biotechnology and industrial applications. In: Pharmaceutical biotechnology. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, pp 1–8. CrossRefGoogle Scholar
  8. Mane P, Tale V (2015) Overview of microbial therapeutic enzymes. Int J Curr Microbiol App Sci 4(4):17–26Google Scholar
  9. Matousek J (2001) Ribonucleases and their antitumor activity. Comp Biochem Physiol Toxicol Pharmacol CBP 129(3):175–191CrossRefGoogle Scholar
  10. Moelling K, Broecker F, Kerrigan JE (2014) RNase H: specificity, mechanisms of action, and antiviral target. Method Mol Biol (Clifton, NJ) 1087:71–84. CrossRefGoogle Scholar
  11. Mulyasuryani A, Srihardiastutie A (2011) Conductimetric biosensor for the detection of uric Acid by immobilization uricase on nata de coco membrane-pt electrode. Anal Chem Insight 6:47–51. SAGE PublicationsCrossRefGoogle Scholar
  12. National Institute of Diabetes and Digestive and Kidney Diseases (2014) Lactose intolerance. NIDDK: Health Information, JuneGoogle Scholar
  13. O’Sullivan BP, Freedman SD (2009) Cystic fibrosis. Lancet 373(9678):1891–1904. CrossRefPubMedGoogle Scholar
  14. Oshiro BT (1999) The semisynthetic penicillins. Primary Care Update for OB/GYNS 6(2):56–60. CrossRefGoogle Scholar
  15. Pieters R et al (2011) L-asparaginase treatment in acute lymphoblastic leukemia. Cancer 117(2):238–249. CrossRefPubMedGoogle Scholar
  16. Ries M (2017) Enzyme replacement therapy and beyond—in memoriam Roscoe O. Brady, M.D. (1923–2016). J Inherit Metab Dis 40(3):343–356. CrossRefPubMedGoogle Scholar
  17. Salzer WL et al (2014) Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia. Ann N Y Acad Sci 1329(1):81–92. CrossRefPubMedGoogle Scholar
  18. Sani RK, Navanietha Krishnaraj R (n.d.) Extremophilic enzymatic processing of lignocellulosic feedstocks to bioenergyGoogle Scholar
  19. Shak S et al (1990) Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci U S A 87(23):9188–9192CrossRefGoogle Scholar
  20. Simonsohn B (2000) Healing power of papaya a holistic health handbook on how to avoid acidosis, allergies, and other health disorders. Pilgrims Publ, VaranasiGoogle Scholar
  21. Sistla S, Rao DN (2004) S-adenosyl-L-methionine-dependent restriction enzymes. Crit Rev Biochem Mol Biol 39(1):1–19. CrossRefPubMedGoogle Scholar
  22. Stolarow J et al (2015) Immobilization of trypsin in organic and aqueous media for enzymatic peptide synthesis and hydrolysis reactions. BMC Biotechnol 15:77. CrossRefPubMedPubMedCentralGoogle Scholar
  23. Vellard M (2003) The enzyme as drug: Application of enzymes as pharmaceuticals. Curr Opin Biotechnol 14(4):444–450. CrossRefPubMedGoogle Scholar
  24. Verma N et al (2007) E. coli K-12 asparaginase-based asparagine biosensor for leukemia. Artif Cells Blood Substit Biotechnol 35(4):449–456. CrossRefGoogle Scholar
  25. What is leukaemia, its causes and signs and symptoms|Leukaemia CARE (n.d.)Google Scholar
  26. Zschocke J et al (2016) JIMD reports, vol 28. Springer, Berlin. Google Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  • Bhupender Singu
    • 1
  • Uday Annapure
    • 1
  1. 1.Department of Food Engineering and TechnologyInstitute of Chemical TechnologyMatunga, MumbaiIndia

Personalised recommendations